West Pharmaceutical
717 hedge funds and large institutions have $28.2B invested in West Pharmaceutical in 2022 Q1 according to their latest regulatory filings, with 75 funds opening new positions, 245 increasing their positions, 279 reducing their positions, and 82 closing their positions.
1.3% more ownership
Funds ownership: 93.8% → 95.1% (+1.3%)
6% less call options, than puts
Call options by funds: $79.6M | Put options by funds: $84.4M
9% less first-time investments, than exits
New positions opened: 75 | Existing positions closed: 82
2% less funds holding
Funds holding: 730 → 717 (-13)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
12% less capital invested
Capital invested by funds: $32B → $28.2B (-$3.8B)
12% less repeat investments, than reductions
Existing positions increased: 245 | Existing positions reduced: 279
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIAS
CFS Investment Advisory Services
Totowa,
New Jersey
|
+$605M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$286M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$209M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$154M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$67.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$97.9M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$85.5M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$74.6M |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$59.1M |
| 5 |
Morgan Stanley
New York
|
-$58.3M |
WST Hedge Fund Activity: Q1 2022 in Review
717 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q1 2022, worth a combined $28.2B — down 12% from $32B a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of WST and 75 opened new positions — a net loss of 7 holders — while 279 trimmed existing stakes and 245 added.
The largest buyer was CFS Investment Advisory Services, adding an estimated $605M. The largest seller was Arrowstreet Capital, cutting an estimated $97.9M.
- 717 institutional investors held West Pharmaceutical (WST) as of Q1 2022, down from 730 in Q4 2021.
- Funds reported $28.2B of West Pharmaceutical stock for Q1 2022, down 12% quarter-over-quarter.
- 75 funds opened new West Pharmaceutical positions in Q1 2022 and 82 closed out, a net change of -7 holders.
- The largest West Pharmaceutical buyer in Q1 2022 was CFS Investment Advisory Services, an estimated $605M added.
- The largest West Pharmaceutical seller in Q1 2022 was Arrowstreet Capital, an estimated $97.9M sold.
Based on aggregated 13F filings for Q1 2022.